Maxcyte Inc Feed

	Est. tid*
2027-03-15	08:00	Bokslutskommuniké 2026
2026-11-05	21:05	Kvartalsrapport 2026-Q3
2026-08-06	21:05	Kvartalsrapport 2026-Q2
2026-05-07	21:05	Kvartalsrapport 2026-Q1
2026-03-24	-	Bokslutskommuniké 2025
2025-11-05	-	Kvartalsrapport 2025-Q3
2025-08-06	-	Kvartalsrapport 2025-Q2
2025-06-18	-	Årsstämma
2025-05-08	-	Kvartalsrapport 2025-Q1
2025-03-11	-	Bokslutskommuniké 2024
2024-11-07	-	Kvartalsrapport 2024-Q3
2024-08-07	-	Kvartalsrapport 2024-Q2
2024-06-11	-	Årsstämma
2024-05-08	-	Kvartalsrapport 2024-Q1
2024-03-13	-	Bokslutskommuniké 2023
2023-11-08	-	Kvartalsrapport 2023-Q3
2023-08-09	-	Kvartalsrapport 2023-Q2
2023-06-22	-	Årsstämma
2023-05-10	-	Kvartalsrapport 2023-Q1
2023-03-15	-	Bokslutskommuniké 2022
2022-11-09	-	Kvartalsrapport 2022-Q3
2022-08-10	-	Kvartalsrapport 2022-Q2
2022-06-29	-	Årsstämma
2022-05-09	-	Kvartalsrapport 2022-Q1
2022-03-22	-	Bokslutskommuniké 2021
2021-11-10	-	Kvartalsrapport 2021-Q3
2021-09-13	-	Kvartalsrapport 2021-Q2

Land	USA
Lista	52
Sektor	Hälsovård
Industri	Medicinteknik

2026-04-29 22:05:00 MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

2026-03-24 21:05:00 MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

2026-03-23 13:05:00 MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

2026-02-24 14:05:00 MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

2026-02-23 22:05:00 MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

2026-01-12 14:05:00 MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

2025-11-12 22:08:00 MaxCyte Announces Planned CFO Transition in 2026

2025-11-12 22:05:00 MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

2025-11-05 14:05:00 MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

2025-10-08 14:05:00 MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

2025-10-06 14:05:00 MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

2025-09-22 22:30:48 MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

2025-08-04 14:05:00 MaxCyte Signs Platform License Agreement with Adicet Bio

2025-07-31 14:05:00 MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

2025-07-09 14:05:00 MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

2025-06-11 08:00:00 MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies 168,50 GBP | -2,03%

2025-05-07 22:05:00 MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance 203,00 GBP | 0,00%

2025-04-10 08:00:00 MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 192,00 GBP | +4,92%

2025-03-11 21:05:00 MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance 265,00 GBP | +0,38%

2025-02-12 08:00:00 MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs 332,00 GBP | -2,35%

2025-02-07 08:00:00 MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference 359,00 GBP | 0,00%

2025-01-30 08:00:00 MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments 377,00 GBP | +0,53%

2025-01-13 09:05:00 MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results 368,00 GBP | +4,84%

2024-12-23 08:00:00 MaxCyte Announces Retirement of Board Member Art Mandell 327,00 GBP | -0,91%

2024-12-09 08:00:00 MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance 315,00 GBP | +12,90%

2024-11-13 14:05:00 MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics 270,00 GBP | -1,82%

2024-11-06 22:05:00 MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance 303,00 GBP | +4,84%

2024-10-31 13:05:00 MaxCyte to Participate in Two Upcoming Investor Conferences 279,00 GBP | +1,45%

2024-10-15 14:05:00 MaxCyte Appoints Cynthia Collins to its Board of Directors 292,00 GBP | -1,02%

2024-10-11 14:05:00 MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 285,00 GBP | -2,06%

2024-10-10 14:05:00 MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer 291,00 GBP | +2,83%

2024-09-16 08:00:00 MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases 311,00 GBP | +3,67%

2024-09-05 22:05:00 MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference 304,00 GBP | -5,00%

2024-08-06 22:05:00 MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance 335,00 GBP | +2,13%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Maxcyte Inc

Kalender

Beskrivning

Vem äger bolaget?

Maxcyte Inc

Kalender

Beskrivning

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden